1. MUC1-C dictates neuroendocrine lineage specification in pancreatic ductal adenocarcinomas. (17th October 2021) Authors: Luan, Zhou; Morimoto, Yoshihiro; Fushimi, Atsushi; Yamashita, Nami; Suo, Wenhao; Bhattacharya, Atrayee; Hagiwara, Masayuki; Jin, Caining; Kufe, Donald Journal: Carcinogenesis Issue: Volume 43:Number 1(2022) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MUC1-C IS A DRUGGABLE TARGET FOR TREATMENT OF COLITIS AND PROGRESSION OF COLITIS-ASSOCIATED COLORECTAL CANCER. (21st January 2021) Authors: Morimoto, Yoshihiro; Li, Wei; Zhang, Ning; Takahashi, Hidekazu; Jin, Caining; Kufe, Donald Journal: Inflammatory bowel diseases Issue: Volume 27(2021)Supplement 1 Page Start: S3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer. (2nd September 2017) Authors: Bouillez, Audrey; Adeegbe, Dennis; Jin, Caining; Hu, Xiufeng; Tagde, Ashujit; Alam, Maroof; Rajabi, Hasan; Wong, Kwok-Kin; Kufe, Donald Journal: Oncoimmunology Issue: Volume 6:Number 9(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗